Therapeutic Variables in Cataract Surgery

This study has been completed.
Information provided by:
Innovative Medical Identifier:
First received: November 30, 2006
Last updated: August 17, 2007
Last verified: August 2007
The purpose of this study is to compare patient outcomes in following cataract surgery in patients randomized to one of two surgical kits.

Condition Intervention Phase
Cataract Surgery
Drug: Gatifloxacin
Drug: Ketorolac LS
Drug: Pred Forte
Drug: Moxifloxacin
Drug: Nepafenac
Drug: EconoPred Plus
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Resource links provided by NLM:

Further study details as provided by Innovative Medical:


Genders Eligible for Study:   Both

Inclusion Criteria:

  • Males or females scheduled to undergo cataract surgery
  • Patients can be receiving monofocal IOLs only
  • Likely to complete all study visits and able to provide informed consent
  • Visual potential of 20/25 or better

Exclusion Criteria:

  • Known contraindications to any study medication or ingredients
  • Active ocular diseases or uncontrolled systemic disease
  • Active ocular allergies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00407017

United States, Florida
The Center for Excellence in Eye Care
Miami, Florida, United States, 33176
Sponsors and Collaborators
Innovative Medical
Principal Investigator: William Trattler, MD The Center For Excellence in Eye Care
  More Information

No publications provided Identifier: NCT00407017     History of Changes
Other Study ID Numbers: 5264-T
Study First Received: November 30, 2006
Last Updated: August 17, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Eye Diseases
Lens Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on November 24, 2015